• HOME>
  • R&D>
  • Research Collaborations, In-licenses and Acquisitions

Research Collaborations, In-licenses and Acquisitions

Research Collaboration

Targeting the continual creation of new drugs, we are promoting research collaborations with various parties inside and outside Japan, including universities, research institutions and venture companies possessing innovative technologies.

Toward positive strategic Investment on Alliance and Licensing

We are collecting information in various forms including investment into "DEFTA Healthcare Technologies, L.P." in addition to a bio-venture fund "Apposite Healthcare Fund, L.P." and "Remiges BioPharma Fund, L.P."

Investment destination Investment fields
Apposite Healthcare Fund, L.P. Life sciences, healthcare services
Remiges BioPharma Fund, L.P. Pharmaceuticals research and
development and other life sciences
DEFTA Healthcare Technologies, L.P. Leading-edge medical treatments and
regenerative medicine, next-generation
medical devices, and healthcare IoT/ICT

Major External Collaboration

Kyoto University : Project for drug discovery research focusing on the regulatory mechanisms of cell - cell interactions in tumor microenvironment (DSK Project)

Kyoto University and Sumitomo Dainippon Pharma unite their expertise (for instance, the ample experience and knowledge from basic and clinical researches in Kyoto University and the knowledge and resources in drug R&D and regulatory affairs, and management skills in Sumitomo Dainippon Pharma) to establish a research center where selected young scientists are supported to establish their own research units and to pursue their original and promising ideas that will eventually lead to the development of new drugs, materials, or concepts useful for cancer prevention, diagnosis, or therapy.

The Kitasato Institute: Joint Drug Discovery Research for AMR "KS-Project"

Sumitomo Dainippon Pharma is conducting joint research with a drug discovery group led by Dr. Satoshi Omura, Distinguished Emeritus Professor of Kitasato University and the 2015 laureate of the Nobel Prize in Physiology or Medicine, with the aim of discovering new drugs against infections caused by bacteria with antimicrobial resistance (AMR). This joint R&D initiative was selected by the Japan Agency for Medical Research and Development (AMED) for its Cyclic Innovation for Clinical Empowerment (CiCLE) grant program.

The Center for iPS Cell Research and Application (CiRA)

  • This joint research collaboration between industry and academia, focusing on a rare intractable disease caused by genetic mutation, aims to use induced pluripotent stem cells (iPS cells) to identify the pathognomonic mechanism of the disease, identify the most disease-specific target molecule from various pathological changes of signal transduction, and screen specific inhibitors against the signal pathway. As a result, the aim is to create an epoch-making treatment to suppress detrimental conditions in patients.
  • CiRA and Sumitomo Dainippon Pharma are conducting joint research and development to establish the world's first Parkinson's disease treatment using allogeneic iPS cell-derived dopaminergic neural progenitor cells.

The Center for iPS Cell Research and Application (CiRA) and Hitachi Ltd.

CiRA, Hitachi Ltd., and Sumitomo Dainippon Pharma are jointly developing the base technology and evaluation methods to establish a production process for dopaminergic neural progenitor cells. This will be used to develop the world's first Parkinson's disease treatment using allogeneic iPS cell-derived dopaminergic neural progenitor cells. These endeavors are part of the "Project Focused on Developing Key Evaluation Technology: Evaluation for Industrialization in the Field of Regenerative Medicine" commissioned by The Japan Agency for Medical Research and Development (AMED).

Healios K.K.

Healios K.K. and Sumitomo Dainippon Pharma are conducting joint development in Japan of iPS cell-derived retinal pigment epithelial cells (RPE cells) for the treatment of age-related macular degeneration and other eye diseases.

Keio University and National Hospital Organization Osaka National Hospital

Under the Research Center Network for Realization of Regenerative Medicine, a joint initiative between government, industry and academia, Sumitomo Dainippon Pharma, together with the National Hospital Organization Osaka National Hospital, is taking part as a contributing organization in the Keio University (Professor Hideyuki Okano) project on "Regenerative medicine for spinal cord injury and stroke using iPS cell-derived neural precursor cells." The goal of the project is to develop a treatment for the transplantation of iPS cell-derived neural precursor cells for spinal cord injury.

RIKEN

In basic research, Sumitomo Chemical Co., Ltd. in partnership with RIKEN has succeeded in generating a three-dimensional retina from human embryonic stem cells, a world first. Following on from this, Sumitomo Dainippon Pharma aims to create a treatment available using an allogeneic iPS cell-derived three-dimensional retina.

JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. and Sumitomo Dainippon Pharma are conducting joint research applying JCR's proprietary blood-brain barrier (BBB) penetration technology "J-Brain Cargo" to the discovery of new treatments in the psychiatry and neurology areas.

Promoting Strategic Investment to Acquire Companies and In-license Development Products

From the viewpoint of expanding the development pipeline, we are actively promoting strategic investment to acquire companies and in-license development products. In relation to in-licensing, we consider a wide variety of late development stage products as a priority with a focus on Psychiatry & Neurology, oncology and specialty areas.

Major recent acquisitions

Company acquired Date acquired Major development products
Product code Development stage Development location Category
Tolero Pharmaceutical, Inc. (U.S.) January 2017 alvocidib (Generic name) Phase 2 U.S./Canada Anticancer drug
TP-0903 Phase 1 U.S. Anticancer drug
TP-1287 Preclinical U.S.
TP-0184 Preclinical U.S.
Cynapsus Therapeutics Inc. (Canada)
(currently Sunovion CNS Development Canada ULC)
October 2016 APL-130277 Phase 3 U.S. Therapeutic agent for Parkinson's disease

Major recent in-licensed products

Brand name/
Generic name/
Product code
Indication/
Proposed
indication
Licensed
from
Date of
licensing
Development
stage
Territory
UTIBRON™
Neohaler®
Chronic
obstructive
pulmonary
disease
(COPD)
Novartis
(Switzerland)
December
2016
Approved U.S.
SEEBRI™
Neohaler®
ARCAPTA®
Neohaler®
SB623 Chronic
stroke
(cellular
medicine)
SanBio, Inc. (U.S.) September
2014
Phase 2 U.S./
Canada
vatiquinone
(EPI-743)
Mitochondrial
disease
BioElectron
Technology
Corporation
(formerly Edison
Pharma-
ceuticals, Inc.) (U.S.)
March
2013
completed
Phase 2/3
Japan
EPI-589 Neuro-
degenerative
diseases
Phase 2 Japan/
U.S./
Canada
(U.S., Canada:
adults only)
obeticholic acid
(DSP-1747)
Nonalcholic
steatohepatitis
(NASH)
Intercept
Pharma-
ceuticals, Inc.
(U.S.)
March
2011
Phase 2 Japan/
China/
Korea